In this episode of Meso TV, our Director of Patient Services, Julie, talks with Dr. Timothy Yap from MD Anderson Cancer Center about the VT3989 clinical trial for mesothelioma. He explains what this new treatment is, how it works, and what it could mean for patients.
VT3989 is a YAP/TEAD inhibitor, which means it targets signals inside cancer cells that help them grow and survive. By blocking these signals, this treatment may help slow or stop the growth of mesothelioma tumors. Dr. Yap breaks this down in clear, easy-to-understand language for patients and families.
Have questions or interested if this trial will work for you or your loved one? Reach out to our Director of Patient Services, Julie White, by email at [email protected].
Our Sponsors
MesoTV is a program by the Mesothelioma Applied Research Foundation. This program is made possible by our generous sponsors: Belluck Law, Dean Omar Branham Shirley, LLP; Maune Raichle Hartley French & Mudd, LLC (MRHFM); The Gori Law Firm; Merck; Early Luccarelli Sweeney & Meisenkothen, LLC; AstraZeneca
Search our previous episodes for topics/speakers of interest to you at www.curemeso.org/mesotv
